Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro

被引:25
|
作者
Baek, Jong Min [1 ]
Ahn, Sung-Jun [1 ]
Cheon, Yoon-Hee [2 ]
Lee, Myeung Su [3 ,5 ]
Oh, Jaemin [1 ,4 ,5 ]
Kim, Ju-Young [4 ]
机构
[1] Wonkwang Univ, Dept Anat, 344-2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea
[2] Wonkwang Univ, Ctr Metab Funct Regulat, Iksan 570749, South Korea
[3] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, South Korea
[4] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, 344-2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea
基金
新加坡国家研究基金会;
关键词
nicotinamide phosphoribosyltransferase; adipokine; osteoclast; osteoporosis; COLONY-ENHANCING FACTOR; CELLS; RANKL; BIOSYNTHESIS; PATHWAYS; PROTEINS; SURVIVAL; SIGNALS; MICE; FOS;
D O I
10.3892/mmr.2016.6069
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The adipokine nicotinamide phosphoribosyltransferase (Nampt), also known as pre-B-cell colony-enhancing factor or the insulin-mimetic hormone visfatin, has a crucial role in the conversion of nicotinamide to nicotinamide mono nucleotide during biosynthesis of the coenzyme nicotinamide adenine dinucleotide. Previous reports have demonstrated the inhibitory effects of Nampt on osteoclast formation from human peripheral blood mononuclear cells and CD14(+) monocytes. However, the effects of Nampt on bone marrow macrophage (BMM)-derived osteoclastogenesis and its precise role in the process remain unclear. The present in vitro study used recombinant Nampt and BMMs as osteoclast precursors demonstrated that Nampt suppresses receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis by decreasing the phosphorylation of various early signal transducers, including c-Jun N-terminal kinase, Akt, glycogen synthase kinase-3 beta, Bruton's tyrosine kinase and phospholipase C gamma-2. In addition, western blotting and reverse transcription-quantitative polymerase chain reaction analysis indicated that Nampt downregulates the mRNA and protein expression levels of c-Fos and nuclear factor of activated T cells, cytoplasmic 1, leading to a decrease in the expression of osteoclast-specific genes including tartrate-resistant acid phosphatase, osteoclast-associated receptor and cathepsin K. However, the bone-resorbing activity of mature osteoclasts treated with Nampt was similar to untreated control osteoclasts. This finding indicates that Nampt exerts its anti-osteoclastogenic activity by targeting osteoclast precursor cells rather than mature osteoclasts. Consequently, the present study demonstrated that Nampt acts as a negative regulator of RANKL-mediated differentiation of BMMs into osteoclasts, suggesting the potential therapeutic targets to treat bone-related disorders such as osteoporosis.
引用
收藏
页码:784 / 792
页数:9
相关论文
共 50 条
  • [21] Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo
    Sakai, Eiko
    Aoki, Yuri
    Yoshimatsu, Masako
    Nishishita, Kazuhisa
    Iwatake, Mayumi
    Fukuma, Yutaka
    Okamoto, Kuniaki
    Tanaka, Takashi
    Tsukuba, Takayuki
    PHYTOMEDICINE, 2016, 23 (08) : 828 - 837
  • [22] Placotylene A, an Inhibitor of the Receptor Activator of Nuclear Factor-.B Ligand-Induced Osteoclast Differentiation, from a Korean Sponge Placospongia sp.
    Kim, Hiyoung
    Kim, Kwang-Jin
    Yeon, Jeong-Tae
    Kim, Seong Hwan
    Won, Dong Hwan
    Choi, Hyukjae
    Nam, Sang-Jip
    Son, Young-Jin
    Kang, Heonjoong
    MARINE DRUGS, 2014, 12 (04) : 2054 - 2065
  • [23] Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand
    Itoh, K
    Udagawa, N
    Katagiri, T
    Iemura, S
    Ueno, N
    Yasuda, H
    Higashio, K
    Quinn, JMW
    Gillespie, MT
    Martin, TJ
    Suda, T
    Takahashi, N
    ENDOCRINOLOGY, 2001, 142 (08) : 3656 - 3662
  • [24] Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ)
    Odkhuu, Erdenezaya
    Koide, Naoki
    Haque, Abedul
    Tsolmongyn, Bilegtsaikhan
    Naiki, Yoshikazu
    Hashimoto, Shoji
    Komatsu, Takayuki
    Yoshida, Tomoaki
    Yokochi, Takashi
    IMMUNOLOGY LETTERS, 2012, 142 (1-2) : 34 - 40
  • [25] Activation of Liver X Receptor (LXR) Inhibits Receptor Activator of Nuclear Factor κB Ligand (RANKL)-induced Osteoclast Differentiation in an LXR β-dependent Mechanism
    Remen, Kirsten M. Robertson
    Henning, Petra
    Lerner, Ulf H.
    Gustafsson, Jan-Ake
    Andersson, Goran
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (38) : 33084 - 33094
  • [26] Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell cl and carbonic anhydrase 2
    Nakagawa, Takayuki
    Ohta, Kouji
    Kubozono, Kazumi
    Ishida, Yoko
    Naruse, Takako
    Takechi, Masaaki
    Kamata, Nobuyuki
    ARCHIVES OF ORAL BIOLOGY, 2015, 60 (04) : 557 - 565
  • [27] Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation
    Kim, Ju Ang
    Ihn, Hye Jung
    Park, Ju-Young
    Lim, Jiwon
    Hong, Jung Min
    Kim, Sang Hyun
    Kim, Shin-Yoon
    Shin, Hong-In
    Park, Eui Kyun
    INTERNATIONAL ORTHOPAEDICS, 2015, 39 (01) : 173 - 182
  • [28] Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation
    Ju Ang Kim
    Hye Jung Ihn
    Ju-Young Park
    Jiwon Lim
    Jung Min Hong
    Sang Hyun Kim
    Shin-Yoon Kim
    Hong-In Shin
    Eui Kyun Park
    International Orthopaedics, 2015, 39 : 173 - 182
  • [29] In vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells
    Granchi, D
    Amato, I
    Battistelli, L
    Avnet, S
    Capaccioli, S
    Papucci, L
    Donnini, M
    Pellacani, A
    Brandi, ML
    Giunti, A
    Baldini, N
    INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (06) : 829 - 838
  • [30] Palmatine Attenuates Osteoclast Differentiation and Function through Inhibition of Receptor Activator of Nuclear Factor-κB Ligand Expression in Osteoblast Cells
    Lee, Ji-Won
    Mase, Naomi
    Yonezawa, Takayuki
    Seo, Hwa-Jeong
    Jeon, Won Bae
    Cha, Byung Yoon
    Nagai, Kazuo
    Woo, Je-Tae
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (10) : 1733 - 1739